CILEST

In 2012 the Transparency Committee considers that, taking into account both the increased risk of venous thromboembolic events and the lack of demonstrated benefit in terms of clinical safety in women exposed to third-generation oral contraceptives compared with second- or first-generation oral contraceptives, the actual benefit of these proprietary medicinal products CILEST must be regarded as insufficient for reimbursement by National Health Insurance.